FDA Approval Summary: Retifanlimab for the treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal

Clinical Cancer Research · Published 2026-08-05 · DOI 10.1158/1078-0432.ccr-26-0618

Free full text

Authors (8)

Shruti U. Gandhy, Sandra J. Casak, May Tun Saung, Pallavi S. Mishra-Kalyani, Shenghui Tang, Doris Auth, R. Angelo de Claro, Steven J. Lemery

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Gandhy, S., Casak, S., Saung, M., et al. (2026). FDA Approval Summary: Retifanlimab for the treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-26-0618

Related articles

• Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial · Clinical Cancer Research · 2026 · Same journal
• Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial · Clinical Cancer Research · 2026 · Same journal
• First-in-human, open-label, single-arm phase 1 study of [211At] meta-astatobenzylguanidine in patients with pheochromocytoma or paraganglioma · Clinical Cancer Research · 2026 · Same journal
• Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in patients with Advanced Hepatocellular Carcinoma · Clinical Cancer Research · 2026 · Same journal
• Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT) · Clinical Cancer Research · 2026 · Same journal
• Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study · Clinical Cancer Research · 2026 · Same journal
• Preclinical characterization of CLSP-1025, a first-in-class, mutation-specific T-cell engager targeting a neoantigen derived from a common p53 mutation · Clinical Cancer Research · 2026 · Same journal
• Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial · Clinical Cancer Research · 2026 · Same journal
• Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight loss (A-NEW) Study · Clinical Cancer Research · 2026 · Same journal
• A phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy in patients with advanced biliary tract cancer: BilT-02 · Clinical Cancer Research · 2026 · Same journal